Xiaoying Zhao

Xiaoying Zhao

Auto-generated profile, based on publicly available information

Xiaoying Zhao

Department of Hematology, the Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310009, China

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2014 in World Journal of Gastroenterology
Verified
Journal Article
Open access
XJXue-Li Jin
Xue-Li Jin
ZWZhao-Hong Wang
Zhao-Hong Wang
XXXi-Bin Xiao
Xi-Bin Xiao
LHLian-Sheng Huang
Lian-Sheng Huang
XZXiao-Ying Zhao
Xiao-Ying Zhao
Blue rubber bleb nevus syndrome (BRBNS) is a rare disease characterized by multiple venous malformations and hemangiomas in the skin and visceral organs. The lesions often involve the cutaneous and gastrointestinal systems. Other organs can also be involved, such as the central nervous system, liver, and muscles. The most common symptoms are gastrointestinal bleeding and secondary iron deficiency anemia. The syndrome may also present with severe complications such as rupture, intestinal torsion, and intussusception, and can even cause death. Cutaneous malformations are usually asymptomatic and do not require treatment. The treatment of gastrointestinal lesions is determined by the extent of intestinal involvement and severity of the disease. Most patients respond to supportive therapy, such as iron supplementation and blood transfusion. For more significant hemorrhages or severe complications, surgical resection, endoscopic sclerosis, and laser photocoagulation have been proposed. Here we present a case of BRBNS in a 45-year-old woman involving 16 sites including the scalp, eyelid, orbit, lip, tongue, face, back, upper and lower limbs, buttocks, root of neck, clavicle area, superior mediastinum, glottis, esophagus, colon, and anus, with secondary severe anemia. In addition, we summarize the epidemiology, clinical manifestations, diagnosis, differential diagnosis and therapies of this disease by analyzing all previously reported cases to enhance the awareness of this syndrome.

18 September 2009 in International Journal of Experimental Pathology
Verified
Journal Article
Closed access
PDF file
ZLZhu Lei
Zhu Lei
ZXZhao Xiaoying
Zhao Xiaoying
LXLu Xingguo
Lu Xingguo

23 February 2013 in Journal of Clinical Immunology
Verified
Journal Article
Closed access
PDF file
XYXu-Yan Yang
Xu-Yan Yang
HWHui-Ying Wang
Hui-Ying Wang
XZXiao-Ying Zhao
Xiao-Ying Zhao
LWLi-Juan Wang
Li-Juan Wang
QLQing-Hua Lv
Qing-Hua Lv
QWQing-Qing Wang
Qing-Qing Wang

4 December 2009 in Acta Pharmacologica Sinica
Verified
Journal Article
Closed access
YLYun Liang
Yun Liang
RXRong-Zhen Xu
Rong-Zhen Xu
LZLei Zhang
Lei Zhang
XZXiao-Ying Zhao
Xiao-Ying Zhao

27 March 2019 in BMC Cancer
Verified
Journal Article
Open access
PDF file
LQLiping Qiu
Liping Qiu
HZHanlu Zheng
Hanlu Zheng
XZXiaoying Zhao
Xiaoying Zhao
Programmed cell death receptor 1 ligand 1 (PD-L1) expression in various tumors, including hematologic malignancies, has recently become a research topic of great interest. We performed a meta-analysis to evaluate the prognostic and clinicopathological value of PD-L1 expressed in tumor cells of patients with diffuse large B-cell lymphoma (DLBCL). Relevant studies were identified from PubMed, EMBASE, Web of Science and the Cochrane Library. The hazard ratio (HR) and 95% confidence interval (95% CI) were used for analyzing survival outcomes, and the odds ratio (OR) was used for analyzing clinicopathological parameters. Pooled results showed that tumor cell PD-L1 expression is associated with poor overall survival (OS) (HR = 2.128, 95% CI: 1.341–3.378, P = 0.001), the non-germinal center B-cell-like subtype (OR = 2.891, 95% CI: 2.087–4.003, P < 0.000), high international prognostic index score (3–5) (OR = 1.552, 95% CI: 1.111–2.169, P = 0.010), B symptoms (OR = 1.495, 95% Cl: 1.109–2.015, P = 0.008), positive MUM1 expression (OR = 3.365, 95% Cl: 1.578–7.175, P = 0.002) and negative BCL6 expression (OR = 0.414, 95% Cl: 0.217–0.792, P = 0.008). Sensitivity analysis showed that there was no publication bias among these studies. Our meta-analysis supported the idea that tumor cell PD-L1 expression may represent a promising biomarker for predicting poor prognosis and is associated with adverse clinicopathologic features in DLBCL patients.

9 March 2009 in Acta Pharmacologica Sinica
Verified
Journal Article
Closed access
YWYan-Lin Wei
Yan-Lin Wei
LXLei Xu
Lei Xu
YLYun Liang
Yun Liang
XXXiao-Hua Xu
Xiao-Hua Xu
XZXiao-Ying Zhao
Xiao-Ying Zhao